Enlivex Therapeutics Stock Jumps On Initiation Of Another Mid-Stage COVID-19 TrialBenzinga • 08/16/21
Enlivex: After Review of Phase II Data, Israeli Ministry of Health Authorizes Initiation of a Multi-Center, Randomized Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 PatientsGlobeNewsWire • 08/15/21
Enlivex Announces Second Quarter 2021 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/09/21
Enlivex Hires Biotech Industry Veteran Tzvi Palash to Lead the Design and Construction of its New cGMP Allocetra Manufacturing PlantGlobeNewsWire • 08/02/21
Enlivex Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in SepsisGlobeNewsWire • 05/18/21
Enlivex: Interesting Macrophage Reprogramming Science Targets $33B Sepsis MarketSeeking Alpha • 03/29/21
Enlivex To Study Allocetra Combined With Checkpoint Inhibitors In Solid Tumor SettingsBenzinga • 03/22/21
Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra™ in Combination with Immune Checkpoint InhibitorsGlobeNewsWire • 03/22/21
Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint InhibitorsGlobeNewsWire • 03/01/21
Enlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis and GvHD Using Allocetra ImmunotherapyGlobeNewsWire • 02/16/21
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary SharesGlobeNewsWire • 02/12/21
Enlivex Increases Previously Announced Bought Deal Offering to Approximately $46.0 Million of Ordinary SharesGlobeNewsWire • 02/10/21
Enlivex Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program UpdateGlobeNewsWire • 02/03/21
Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxivGlobeNewsWire • 12/21/20
Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 PatientsGlobeNewsWire • 12/03/20
Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with AllocetraGlobeNewsWire • 11/18/20
Enlivex Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company's Board of DirectorsGlobeNewsWire • 11/17/20